ReviewClinical ophthalmology (Auckland, N.Z.)2014
Ranibizumab for the treatment of degenerative ocular conditions.
Review in Clinical ophthalmology (Auckland, N.Z.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.International journal of nanomedicine · 2025Review
- Monoclonal Antibodies for the Treatment of Ocular Diseases.Journal of clinical medicine · 2024Review
- Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies.Drug design, development and therapy · 2023Review
- Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies.Drug design, development and therapy · 2022Review
- Evolution of intravitreal therapy for retinal and macular disorders.The Journal of international medical research · 2020Article
- Pharmacology Study of the Multiple Angiogenesis Inhibitor RC28-E on Anti-Fibrosis in a Chemically Induced Lung Injury Model.Biomolecules · 2019Article
- Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.The Journal of international medical research · 2019Review
- Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep.International journal of ophthalmology · 2017Article
- IDO1 is an Integral Mediator of Inflammatory Neovascularization.EBioMedicine · 2016Article
- Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach.Medical hypothesis, discovery & innovation ophthalmology journal · 2015Article
- Principles of Ocular Pharmacology.Handbook of experimental pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isoforms of VEGF-A, is still the gold standard treatment for the majority of these pathological entities. In this review, we present the results of the most important clinical trials concerning the efficacy and safety of ranibizumab for the treatment of degenerative ocular conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.